Bumrungrad International Hospital raises the bar of innovative cancer treatment with comprehensive genomic testing in Thailand
Bangkok, Thailand – Bumrungrad International Hospital is at the forefront of personalised cancer care with comprehensive genomic testing that will lead to a more accurate diagnosis and better analysis of outcomes for cancer patients.
Bumrungrad International Hospital, a medical tourism and healthcare leader for more than a decade, was the first hospital in Asia to be accredited by Joint Commission International (JCI) for American-equivalent clinical operations standards in 2002. A one-stop-shop of multidisciplinary medicine, Bumrungrad International provides comprehensive care in over 70 specialties clinical and sub-specialties for patients from over 190 nationalities all over the world and underlined its pioneering position in cancer treatment with a commitment to the latest innovations in cancer prevention, treatment, and research.
New comprehensive genomic profiling includes an updated gene list and alterations in the most commonly mutated genes that are known to drive the growth of cancer. New tests detail genomic signatures which can better direct treatment decisions. Since all patients are different, specific individual treatments, often called targeted therapies or precision medicine, are personally customised to each patient and can be more effective than standard cancer treatments.
Dr. Harit Suwanrusme, an Oncology Specialist at Horizon Regional Cancer Center, Bumrungrad International Hospital, stated that today’s technology makes diagnosis faster, more precise and personalised, which is vital since cancer is the leading cause of death in most developed countries.
Dr. Harit, said that some cancers could be found more often in some families. Therefore, genetic prone testing will benefit some patients by giving more information about patient and family members’ genetic prone.“Everybody has a different genetic make-up which makes us susceptible to different diseases and means medication can work in different ways for different people. In some cases, we can use targeted therapy to help control the cancer,” he said. Dr.Harit added that whilst standard treatments are still effective; some cases require greater insights. This is where the new technology that helps assess tumour genomic alterations and could broaden the treatment options for some patients.
Today, comprehensive genomic profiling (CGP) of tumours can provide insight into clinically relevant genetic alterations, with goals of guiding clinical decision-making and augmenting therapeutic options. Bumrungrad International has been collaborated with various partners to provide this well-established diagnostic technology and now able to do some in-house genetic tests including comprehensive liquid tumour biopsy to detect tumour DNA floating in patient’s blood stream. Bumrungrad International Hospital, is one of the only hospitals outside of the United States to utilise IBM Watson for Oncology, an advanced machine-learning AI supporting doctors in diagnoses and treatment plans with the aggregation of all past and current clinical trial and research data. In 2019 Bumrungrad International will start to utilise IBM Watson for genomics as well. For more information please visit our website www.bumrungrad.com.